ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

12 Jan 2026 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

30 Dec 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

15 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

09 Dec 2025 17:07:34 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

06 Dec 2025 08:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

24 Nov 2025 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

06 Nov 2025 16:05:02 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

05 Nov 2025 16:05:02 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

15 Oct 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

27 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

05 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

15 Jul 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

01 Jul 2025 07:30:07 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 May 2025 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

28 May 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

01 May 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

10 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

08 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

11 Feb 2025 16:05:00 By Nasdaq GlobeNewswire